artemis logo

Four different ways to play the AI theme

28 Sept 20265 min read

Key takeaways

When a growth theme becomes as ubiquitous as AI has over the past couple of years, niggling doubts about its sustainability begin to creep in. So how best to play the next stage of this trend? 

Me and the other managers of the Artemis US Select Fund are doing exactly what we did before: looking for stocks where the potential upside outweighs the potential downside by a factor of at least 2:1.

Below we reveal the four groups of companies that we believe will be affected by AI in different ways and how our up/down framework has led us to an investment view on each one.

The hyperscalers

The first and most obvious way to play AI is to invest in the companies leading the charge: tech stalwarts such as Alphabet, Amazon, Meta and Microsoft. 

The main problem with this approach is the excessive amount of investment required by these ‘hyperscalers’ to maintain a leading edge in the technology: AI infrastructure spending among this cohort has hit $1.1trn since 20231, leading to a collapse in short-term cashflows.  

With no guarantee of a return from this enormous outlay, our search for the asymmetric risk/reward trade-off has led us to go underweight this group of companies until we see more evidence of who will come out on top and the likely impact on profits. 

The supply chain

Another well-publicised method of playing the AI theme is through the ‘picks & shovels’ approach: the companies providing the goods and services on which the hyperscalers are spending such enormous amounts of money. In many cases, they can’t spend it fast enough, leading to a supply/demand imbalance which allows the providers to generate supra-normal profits. 

The first beneficiaries of this trend were semiconductor designers (such as Nvidia) and manufacturers (such as Broadcom). These companies have high incremental margins (meaning any increase in revenue results in an exponential increase in profitability) so their cashflows spiked just as those of the hyperscalers were beginning to collapse.  

Today we would also include providers of memory (Seagate), energy (Bloom), networking for data centres (Applied Optoelectronics and Coherent) and skilled labour (Comfort Systems). 

We see nothing to suggest the supra-normal profits being generated by these companies will come under threat any time soon – especially if the hyperscalers’ spending commitments remain in place. 

The ‘victims’

While we are largely positive on the prospects for companies in the AI supply chain, we are not the only investors who have come round to this view. As a result, few of them look especially cheap on conventional metrics such as the price-to-earnings ratio.  

For investors looking for a margin of safety in the form of a lowly valuation, some of the biggest opportunities from AI may conversely be found in the companies thought to be most at risk of disruption from this technology.  

Fears of obsolescence have pushed down valuations in areas such as software and consultancy, even though earnings growth has in many cases outpaced that of the market.  

Should such fears turn out to be misplaced, investors will reappraise these as fast-growing companies generating healthy levels of free cashflow. Re-ratings will likely follow.   

A good example of one of these companies is database software developer MongoDB, which was hammered in the ‘SaaSpocalypse’. We believe that as more businesses embrace AI applications and agents, they need to be able to access all the various types of information they hold in a timely and consistent manner. MongoDB’s database stores and organises a company’s data in such a way to most effectively provide access as AI proliferates across the business. 

It seems many other investors have come around to our way of thinking – after its share price almost halved between January and April, it has since rebounded past its early-year peak.  

Every single other company on the stock market

One bizarre facet of the AI revolution is the hyperscalers that control it may see less net benefit from the technology than the customers they sell it to. And every company in our investable universe is a potential customer. 

Take an industry such as healthcare. Perhaps the most exciting use-case for AI in this area is at the very start of the process: drug discovery. It is estimated the technology can reduce the time needed for a drug to become a pre-clinical candidate from about five years to between 12 and 18 months.

Going right to the other end of the patient-treatment process, AI is improving productivity even after the point when they have recovered.  

If you undergo a medical procedure in the US, the hospital where it was performed can claim back the cost from your insurer by filling in a form. But the claim will be denied if any part of the form is filled in incorrectly – and funnily enough, the insurance companies have made these forms extraordinarily complex.

However, DNA testing provider Natera has developed AI tools that improve first-time approvals of claims by identifying errors and reducing the likelihood of immediate administrative rejections.


Like every other investor, we are still trying to work out all the ramifications of the AI revolution. But one thing we are already confident about is that a top-down view is not the way to play it. It is inevitable that some of the companies at the leading edge of this technology will flatter to deceive, while others deemed most at risk of disruption will find a way to survive and even thrive.

A continued focus on finding those companies where the potential upside outweighs the potential downside by a factor of at least 2:1 will help us limit the losses when we get it wrong – and just as importantly, maximise the gains when we get it right.

FOR PROFESSIONAL INVESTORS AND/OR QUALIFIED INVESTORS AND/OR FINANCIAL INTERMEDIARIES ONLY. NOT FOR USE WITH OR BY PRIVATE INVESTORS.

CAPITAL AT RISK. All financial investments involve taking risk and the value of your investment may go down as well as up. This means your investment is not guaranteed and you may not get back as much as you put in. Any income from the investment is also likely to vary and cannot be guaranteed.

This is a marketing communication. Before making any final investment decisions, and to understand the investment risks involved, refer to the fund prospectus (or in the case of investment trusts, Investor Disclosure Document and Articles of Association), available in English, and KIID/KID, available in English and in your local language depending on local country registration, available in the literature library.

Risks specific to Artemis US Select Fund

  • Market volatility risk The value of the fund and any income from it can fall or rise because of movements in stockmarkets, currencies and interest rates, each of which can move irrationally and be affected unpredictably by diverse factors, including political and economic events.
  • Currency risk The fund’s assets may be priced in currencies other than the fund base currency. Changes in currency exchange rates can therefore affect the fund's value.

Risks specific to Artemis Funds (Lux) – US Focus

  • Market volatility risk The value of the fund and any income from it can fall or rise because of movements in stockmarkets, currencies and interest rates, each of which can move irrationally and be affected unpredictably by diverse factors, including political and economic events.
  • Currency risk The fund’s assets may be priced in currencies other than the fund base currency. Changes in currency exchange rates can therefore affect the fund's value.
  • Concentration risk The fund may have investments concentrated in a limited number of holdings. This can be more risky than holding a wider range of investments.
  • Charges from capital risk Where charges are taken wholly or partly out of a fund's capital, distributable income may be increased at the expense of capital, which may constrain or erode capital growth.
  • ESG risk The fund may select, sell or exclude investments based on ESG criteria; this may lead to the fund underperforming the broader market or other funds that do not apply ESG criteria. If sold based on ESG criteria rather than solely on financial considerations, the price obtained might be lower than that which could have been obtained had the sale not been required.

Important information

The intention of Artemis’ ‘investment insights’ articles is to present objective news, information, data and guidance on finance topics drawn from a diverse collection of sources. Content is not intended to provide tax, legal, insurance or investment advice and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security or investment by Artemis or any third-party. Potential investors should consider the need for independent financial advice. Any research or analysis has been procured by Artemis for its own use and may be acted on in that connection. The contents of articles are based on sources of information believed to be reliable; however, save to the extent required by applicable law or regulations, no guarantee, warranty or representation is given as to its accuracy or completeness. Any forward-looking statements are based on Artemis’ current opinions, expectations and projections. Articles are provided to you only incidentally, and any opinions expressed are subject to change without notice. The source for all data is Artemis, unless stated otherwise. The value of an investment, and any income from it, can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.